Clinical trials: Gastric/Esophageal Cancer
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs.
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Trial name
- NCT00591123
- Testing
- FOLFOX, 5-FU, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Translational Oncology Research International
Esophageal Cancer, Gastric Cancer
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Anti-angiogenic therapy is a proven therapeutic target in refractory gastric and gastroesophageal junction adenocarcinoma. This trial assessed whether the addition of a high affinity angiogenesis inhibitor, ziv-aflibercept, could…
- Trial name
- NCT01747551
- Testing
- Oxaliplatin, Leucovorin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Healthy
A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
The purpose of this study is to assess the potential effect and safety of multiple oral doses of dexlansoprazole, lansoprazole, omeprazole or esomeprazole, once daily (QD), on the steady-state pharmacokinetics and…
- Trial name
- NCT00942175
- Testing
- Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Takeda
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
- Trial name
- NCT01178944
- Testing
- Laboratory Biomarker Analysis, Oxaliplatin, Pralatrexate
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer
- Trial name
- NCT00607594
- Testing
- saracatinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Neoplasms, Esophageal Neoplasms
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer.
- Trial name
- FOLFIRINOX (NCT01928290)
- Testing
- Irinotecan, Trastuzumab, Oxaliplatin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Healthy, Barrett's Esophagus
Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule
The goal of this research is to test the imaging quality of the modified, larger diameter, tethered Spectrally Encoded Confocal Microscopy (SECM) capsule in healthy subjects, subjects with Barrett's Esophagus (BE), and subjects…
- Conditions
- Healthy, Barrett's Esophagus, Gastric Acid Reflux
- Trial name
- SECM (NCT02445014)
- Testing
- MGH SECM Imaging Capsule
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Metastatic Esophageal Cancer, Gastroesophageal Cancer
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
- Conditions
- Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
- Trial name
- NCT01715233
- Testing
- Docetaxel, Leucovorin, Fluorouracil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Esophagogastric Tumors, Gastric Cancer
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
The purpose of this study is to find out whether treatment with trastuzumab combined with pembrolizumab will improve the clearance of tumor DNA from participants' bodies after surgery.
- Conditions
- Esophagogastric Tumors, Gastric Cancer, Gastric Tumor, Esophageal Cancer
- Trial name
- NCT04510285
- Testing
- Trastuzumab, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer, Gastric Cancer
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00217581
- Testing
- Bevacizumab, Docetaxel, Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, floxuridine, docetaxel, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00448760
- Testing
- Docetaxel, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Miami
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT01212822
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work…
- Trial name
- NCT02213289
- Testing
- Trastuzumab, ABT-806, Bemarituzumab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago